| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2007 | WO2007014264A2 Methods and compositions for the treatment of neuropathies and related disorders |
| 02/01/2007 | WO2007014263A2 Octahydroisoquinoline compounds as opioid receptor modulators |
| 02/01/2007 | WO2007014254A2 Method of treating or preventing tissue deterioration, injury or damage due to hypertrophic muscle disease |
| 02/01/2007 | WO2007014253A2 Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure |
| 02/01/2007 | WO2007014250A2 Abl kinase inhibition |
| 02/01/2007 | WO2007014248A2 Method of reducing food intake |
| 02/01/2007 | WO2007014226A2 Compounds for the treatment of neurodegeneration and stroke |
| 02/01/2007 | WO2007014219A2 Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis |
| 02/01/2007 | WO2007014214A2 Introverted cucurbituril compounds |
| 02/01/2007 | WO2007014210A2 Compositions and methods for the reduction of post-operative pain |
| 02/01/2007 | WO2007014198A1 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders |
| 02/01/2007 | WO2007014155A2 Method for treating sickle cell disease and sickle cell disease sequelae |
| 02/01/2007 | WO2007014132A2 Hmgcr isoforms in prediction of efficacy and identification of cholesterol-modulating compounds |
| 02/01/2007 | WO2007014124A2 High drug load formulations and dosage forms |
| 02/01/2007 | WO2007014054A2 Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| 02/01/2007 | WO2007014049A2 Heparin compositions and selectin inhibition |
| 02/01/2007 | WO2007014023A1 Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv |
| 02/01/2007 | WO2007014012A2 Compositions and methods for wood preservation |
| 02/01/2007 | WO2007014011A2 N-(arylamino)-sulfonamide inhibitors of mek |
| 02/01/2007 | WO2007014008A2 Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| 02/01/2007 | WO2007013997A2 Inhibition of the raf/mek/p-erk pathway for treating cancer |
| 02/01/2007 | WO2007013987A2 Supplement composition and method of use in enhancement of methylation process |
| 02/01/2007 | WO2007013975A2 Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
| 02/01/2007 | WO2007013965A2 Synthesis of scabronines and analogues thereof |
| 02/01/2007 | WO2007013964A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| 02/01/2007 | WO2007013962A2 Rapid onset and short term modafinil compositions and methods of use thereof |
| 02/01/2007 | WO2007013936A2 Method for treating nervous system disorders and conditions |
| 02/01/2007 | WO2007013929A1 Aniline sulfonamide derivatives and their uses |
| 02/01/2007 | WO2007013922A1 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrobromide or crystals thereof |
| 02/01/2007 | WO2007013868A2 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 02/01/2007 | WO2007013852A1 Modulators |
| 02/01/2007 | WO2007013845A1 Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution |
| 02/01/2007 | WO2007013844A1 Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea |
| 02/01/2007 | WO2007013843A1 Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia |
| 02/01/2007 | WO2007013842A1 Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain |
| 02/01/2007 | WO2007013841A1 Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema |
| 02/01/2007 | WO2007013830A1 Nitrocatechol derivatives as comt inhibitors |
| 02/01/2007 | WO2007013794A1 Ph-controlled pulsatile delivery system, methods for preparation and use thereof |
| 02/01/2007 | WO2007013793A1 Sensitization of immune system against haptenized melanoma antigens |
| 02/01/2007 | WO2007013696A1 Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
| 02/01/2007 | WO2007013694A1 Phenoxyalkanoic acid compound |
| 02/01/2007 | WO2007013691A1 Spiro-cyclic compound |
| 02/01/2007 | WO2007013689A1 Cyclopropanecarboxylic acid compound |
| 02/01/2007 | WO2007013677A1 Potentiator for substance having interferon-like effect |
| 02/01/2007 | WO2007013673A1 Fused heterocycles as lck inhibitors |
| 02/01/2007 | WO2007013661A1 Percutaneously absorbable ophthalmic preparation |
| 02/01/2007 | WO2007013634A1 Emulsified skin external preparation and method for stabilizing the skin external preparation |
| 02/01/2007 | WO2007013633A1 Emulsified skin external preparation and method for stabilizing the skin external preparation |
| 02/01/2007 | WO2007013613A1 Composition containing fucoidan or fucoidan hydrolysate and immunopotentiating material |
| 02/01/2007 | WO2007013609A1 Fucoidan-derived oligosaccharide |
| 02/01/2007 | WO2007013600A1 Neutron capture preparation and use thereof |
| 02/01/2007 | WO2007013590A1 Non-invasive drug delivery system targeting posterior eye tissue using solid composition |
| 02/01/2007 | WO2007013581A1 Sedative composition |
| 02/01/2007 | WO2007013556A1 Composition for prevention of cancer |
| 02/01/2007 | WO2007013547A1 Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
| 02/01/2007 | WO2007013522A1 Simon potato extract, glycosphingolipid derived from simon potato, and process for production of the extract or glycosphingolipid |
| 02/01/2007 | WO2007013501A1 Growth promoting agent and life prolonging agent |
| 02/01/2007 | WO2007013490A1 Aqueous solution preparation containing camptothecins |
| 02/01/2007 | WO2007013477A1 Pharmaceutical composition comprising 2 , 3-dihydro-6-nitroimidazo [2 , 1-b] oxazole derivatives |
| 02/01/2007 | WO2007013421A1 Novel nitrogenated heterocyclic compound |
| 02/01/2007 | WO2007013411A1 Anti-sense nucleic acid derived from organism |
| 02/01/2007 | WO2007013290A1 Anti-inflammatory analgesic agent |
| 02/01/2007 | WO2007013147A1 Angiogenesis inhibitor and vascular regressive agent |
| 02/01/2007 | WO2007013123A1 Cyclodextrins for blood detoxification |
| 02/01/2007 | WO2007013096A1 Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole) |
| 02/01/2007 | WO2007013078A2 Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |
| 02/01/2007 | WO2007013073A2 Modular overhead bridge |
| 02/01/2007 | WO2007013062A1 Composition and method for weight maintenance |
| 02/01/2007 | WO2007013032A2 Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies |
| 02/01/2007 | WO2007012977A2 Steroid kit and foamable composition and uses thereof |
| 02/01/2007 | WO2007012970A1 Graded expression of snail as marker of cancer development and dna damage-based diseases |
| 02/01/2007 | WO2007012963A1 Transdermal system for varenicline |
| 02/01/2007 | WO2007012960A1 Pharmaceutical compositions of eplerenone |
| 02/01/2007 | WO2007012947A2 Method of treating ischemia-reperfusion injury |
| 02/01/2007 | WO2007012906A1 New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents |
| 02/01/2007 | WO2007012900A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/01/2007 | WO2007012870A2 Use of nefopam for the treatment of affective disorders |
| 02/01/2007 | WO2007012841A2 Compositions comprising monobutyrin |
| 02/01/2007 | WO2007012762A1 Novel polysubstituted 1,1-pyridinyloxycyclopropanamine compounds, method for preparing same and pharmaceutical compositions containing same |
| 02/01/2007 | WO2007012761A1 Novel polysubstituted 1,1-pyridinyl aminocyclopropanamine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 02/01/2007 | WO2007012724A1 1,2,4-thiadiazole derivatives antifungal compounds, compositions containing said compounds and the use thereof |
| 02/01/2007 | WO2007012670A2 Compounds derived from 5-benzylidene imidazolidine 2,4-dione and their use as mchr-1 antagonists |
| 02/01/2007 | WO2007012661A1 Hydantoin derived compounds and use thereof as mchr-1 antagonists |
| 02/01/2007 | WO2007012651A1 Isotopically substituted pantoprazole |
| 02/01/2007 | WO2007012650A1 Isotopically substituted proton pump inhibitors |
| 02/01/2007 | WO2007012645A1 Novel lasek laser eye surgery |
| 02/01/2007 | WO2007012626A2 Novel method for producing tiotropium salts |
| 02/01/2007 | WO2007012579A1 Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists |
| 02/01/2007 | WO2007012464A1 Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase |
| 02/01/2007 | WO2007012439A1 Pharmaceutical compositions comprising levetiracetam and process for their preparation |
| 02/01/2007 | WO2007012422A1 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
| 02/01/2007 | WO2007012421A1 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
| 02/01/2007 | WO2007012379A2 Use of 3-hydroxycoumarin derivatives |
| 02/01/2007 | WO2007012335A1 Treatment for all types of cancer, cysts, fibromas, infections, inflammations, anxiety, migraines, hormonal imbalance, ulcers, asthma, crohn's disease, eczema, psoriasis, rheumatism, acne |
| 02/01/2007 | WO2007012285A1 Viral infection resistent single strand deoxynucleosides |
| 02/01/2007 | WO2007012254A1 Rhein conjugates, preparation method thereof and their uses in producing medicines for treating diabetic nephrosis, intestinal adhesion and osteoarthritis |
| 02/01/2007 | WO2007012191A1 Systems and methods for manufacturing liposomes |
| 02/01/2007 | WO2007012183A1 Process for the production of bicalutamide |
| 02/01/2007 | WO2007012180A1 Papain family cysteine protease inhibitors for the treatment of parasitic diseases |
| 02/01/2007 | WO2007012177A1 Zalcitabine (ddc) boosted lamivudine (3tc) compositions for antiretroviral therapy |